FREE EDUCATION PROGRAMME: GLP-1 RA’s, New Decade, New Therapies
Leicester Diabetes Centre and Primary Care Diabetes Europe (PCDE) collaborate to bring healthcare professionals a FREE primary care education programme focusing on GLP-1-Receptor Agonists (RA)
A programme focusing on new and emerging GLP-1 RA therapies: New Decade, New Therapies: Simplifying the Complex - sign up here
This initiative is to educate primary care physicians and their teams across Europe. Prevalence of type 2 diabetes has increased dramatically over the past few years. 20 years ago most people with diabetes were managed in a secondary care setting. Today about 90 per cent of people with diabetes across Western Europe are managed in primary care. This dramatic change in service delivery therefore makes upskilling primary care physicians and the wider primary care team in diabetes management crucial to maintaining good outcomes for patients with diabetes.
A recent consensus from EASD and ADA recognised that patient centred care is important; recognised a major issue with clinical therapeutic inertia but also has a much greater focus on the emerging therapies such as the GLP-1 RA’s and SGLT-2 inhibitors. In particular the GLP-1 RA’s are now positioned earlier in patients with established cardiovascular disease as well as being discussed earlier in the context of reducing hypoglycaemia and minimising weight gain or maximising weight loss. They are also positioned much earlier as an injectable therapy in type 2 diabetes. Because of the rapid availability of new therapies in this area and the opportunities to combine them in more innovative ways, it is really important that primary care and their team are supported in how they can optimise the opportunities offered with the availability of GLP-1 RA’s.
module one: Positioning GLP-1-RA agonist in the management of people with type 2 diabetes
Released March 2020
Webcast chaired by Prof. Melanie Davies where Prof. Kamlesh Khunti and Dr Sam Seidu discuss the positioning GLP-1 RA agonist in the management of people with type 2 diabetes. To sign up and access Module One please click the link here
Learning outcomes include:
Understanding and describing the key aspects of the ADA/EASD Consensus report for management of T2DM, regarding the importance of patient centred care and the decision cycle underpinning assessment, shared decision making and on-going management and support.
Understanding the importance of both glycaemic control, but also the importance of optimising quality of life and reducing complications in the management of T2DM.
Understanding the relevant and recent cardiovascular outcome trials (CVOT’s) and how they have impacted on the choice of classes of glucose lowering therapy in patients with T2DM diabetes based on presence of ASCVD and other important co-morbidities.
Comparing and appraising the current oral and injectable treatments for glycaemic management of people with T2DM and understanding the positioning of GLP-1RA’s.
Understanding the availability of GLP1-RA’s across the class and to understand key differences within the class.
module two: Practical aspects of initiation and titrations of GLP-1 RA and their combinations with other glucose lowering therapies
Released June 2020
eLearning module with webcast discussion chaired by Dr Sam Seidu where Prof. Melanie Davies and Prof. Kamlesh Khunti discuss how to increase confidence in both patients and practitioners when initiating GLP1-RA’s. To sign up and access Module Two please click the link here
Learning outcomes include:
Increasing the confidence on the initiation of GLP1-RA’s and to understand which patient sub-groups would benefit from earlier use of GLP1-RA’s.
Increasing the confidence and competence of practitioners in initiating dose escalating and mitigating side-effects in the use of GLP1-RA’s.
Increasing confidence on the combined use of GLP1-RA’s with other classes of therapies, particularly in combination with basal insulin and SGLT-2’s.
Understanding the positioning of fixed ratio combinations of insulin and GLP1-RA’s and understanding when and how they should be initiated and titrated.
module three: Innovations in GLP-1 RAs
Released 14th November 2020
An interactive discussion based eLearning module with Dr Sam Seidu, Professor Xavier Cos and Professor Stefan Jansson on GLP-1 RAs innovations.
To sign up and access Module Three please click the link here
Learning outcomes include:
To understand the emergent science regarding new innovation in new GLP1-RA’s including the availability of oral GLP-1 RAs.
Through case based discussions and real world scenarios to maximise confidence and competence in using GLP-1 RA therapy across the spectrum of patients with type 2 diabetes.